Regenerx Biopharmaceuticals (Regenerx Biopharmaceuticals) Momentum Rank : 0 (As of Apr. 29, 2024)

View and export this data going back to 2010. Start your Free Trial

What is Regenerx Biopharmaceuticals Momentum Rank?

Regenerx Biopharmaceuticals has the Momentum Rank of 0.

For Momentum Rank, we considered the residual momentum concept that was widely studied by Blitz and his colleagues as well as by Nobel Prize laureates Fama and French. However, we did not find any significant differences in the performances of stocks with different ranks of residual momentum. Therefore, we use traditional momentum instead.

Momentum Rank is determined using the standardized momentum ratio and other momentum indicators. The standardized momentum ratio is the average of the performances from 12 months ago to 1 month ago and 6 months ago to 1 month ago, divided by the beta of the stock over the past 12 months. To calculate the momentum ratio today, we would use the average of the two performance numbers.

For momentum, we found that stock price performance does not have a monotonic correlation with the momentum ratio. The stocks with the highest momentum ratios perform worse than those at about the 70th percentile. Therefore, for the momentum rank, we ranked the stocks at about the 70th percentile of the momentum ratio as the highest at 10.

Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.

Regenerx Biopharmaceuticals Momentum Rank Related Terms

Thank you for viewing the detailed overview of Regenerx Biopharmaceuticals's Momentum Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Regenerx Biopharmaceuticals (Regenerx Biopharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Regenerx Biopharmaceuticals Inc (OTCPK:RGRX) » Definitions » Momentum Rank

Comparable Companies

Traded in Other Exchanges

N/A

Address

15245 Shady Grove Road, Suite 470, Rockville, MD, USA, 20850

Website

https://www.regenerx.com

Regenerx Biopharmaceuticals Inc is focused on the discovery and development of novel molecules to accelerate tissue and organ repair. Its operations are confined to one business segment: the development and marketing of product candidates based on Thymosin Beta 4 (Tß4), an amino acid peptide. The company has formulated Tß4 into three distinct product candidates in clinical development: RGN-259, a preservative-free topical eye drop for regeneration of corneal tissues damaged by injury, disease or other pathology; RGN-137, a topical gel for dermal wounds and reduction of scar tissue; and RGN-352, an injectable formulation to treat cardiovascular diseases, central and peripheral nervous system diseases, and other medical indications that may be treated by systemic administration.

Executives

Aptafin S P A	other: Member of 10% owner group	VIALE SHAKESPEARE 47, ROME L6 00144
Alessandro Noseda	director	C/O 15245 SHADY GROVE ROAD, SUITE 470, ROCKVILLE MD 20850
S.a. Sinaf	10 percent owner	26 BOULEVARD ROYAL, LUXEMBOURG N4 L-2449
Spa Essetifin	10 percent owner	VIA SUDAFRICA 20, ROME L6 00144
Francesca Cavazza	10 percent owner	VIA PONTINA KM 30,400, POMEZIA (ROME) L6 00040
Silvia Cavazza	10 percent owner	VIA PONTINA KM 30,400, POMEZIA (ROME) L6 00040
Enrico Cavazza	10 percent owner	VIA PONTINA KM 30,400, POMEZIA (ROME) L6 00040
Preta Martina Cavazza	10 percent owner	VIA SUDAFRICA 20, ROME L6 00144
Mauro Bove	director	C/O REGENERX BIOPHARMACEUTICALS, INC., 3 BETHESDA METRO CENTER - SUITE 630, BETHESDA MD 20814
R Don Elsey	director	2273 RESEARCH BLVD, SUITE 400, ROCKVILLE MD 20850
J J Finkelstein	director
Joseph C Mcnay	director	3 BETHESDA METRO CENTER STE 700, C/O REGENERX BIOPHARMACEUTICALS INC, BETHESDA MD 20814
Allan L Goldstein	director
Dane R Saglio	officer: Chief Financial Officer
Aria Digital	10 percent owner	22ND FL, PARKVIEW TOWER,, 248 JUNGJAIL-RO, BUNDANG-GU,, SEONGNAM-SI, GYEONGGI-DO M4 463-863